Rapid Micro Biosystems (NASDAQ:RPID) Upgraded to Hold at Wall Street Zen

Rapid Micro Biosystems (NASDAQ:RPID) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Rapid Micro Biosystems presently has an average rating of “Hold” and an average target price of $8.00.

Rapid Micro Biosystems Trading Down 6.0%

Rapid Micro Biosystems stock opened at $2.35 on Friday. The company has a market capitalization of $104.16 million, a price-to-earnings ratio of -2.20 and a beta of 1.38. Rapid Micro Biosystems has a 12 month low of $1.86 and a 12 month high of $4.94. The business’s fifty day simple moving average is $3.92 and its two-hundred day simple moving average is $3.55. The company has a current ratio of 3.31, a quick ratio of 2.36 and a debt-to-equity ratio of 0.57.

Rapid Micro Biosystems (NASDAQ:RPID) last posted its earnings results on Thursday, March 12th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.05). Rapid Micro Biosystems had a negative net margin of 140.30% and a negative return on equity of 95.40%. The firm had revenue of $11.28 million for the quarter, compared to analysts’ expectations of $10.93 million. As a group, equities analysts predict that Rapid Micro Biosystems will post -1.1 earnings per share for the current fiscal year.

Insider Activity at Rapid Micro Biosystems

In other Rapid Micro Biosystems news, major shareholder Longitude Capital Partners Ii, sold 49,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $3.88, for a total transaction of $190,120.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO John J. Addington Wilson sold 9,603 shares of the stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $4.32, for a total value of $41,484.96. Following the transaction, the chief operating officer directly owned 316,762 shares of the company’s stock, valued at $1,368,411.84. The trade was a 2.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 249,705 shares of company stock worth $1,021,364 in the last quarter. Company insiders own 29.96% of the company’s stock.

Institutional Trading of Rapid Micro Biosystems

A number of institutional investors have recently made changes to their positions in the company. Hudson Bay Capital Management LP acquired a new position in Rapid Micro Biosystems in the 3rd quarter valued at $38,000. American Century Companies Inc. boosted its stake in Rapid Micro Biosystems by 46.1% during the 2nd quarter. American Century Companies Inc. now owns 16,922 shares of the company’s stock worth $58,000 after purchasing an additional 5,341 shares during the last quarter. Fifth Lane Capital LP acquired a new stake in Rapid Micro Biosystems during the 4th quarter worth $51,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Rapid Micro Biosystems during the fourth quarter worth $71,000. Finally, Barclays PLC acquired a new stake in shares of Rapid Micro Biosystems in the fourth quarter valued at about $72,000. 52.60% of the stock is owned by institutional investors and hedge funds.

About Rapid Micro Biosystems

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.